{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cystadenocarcinoma",
    "query": {
      "condition": "Cystadenocarcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 125,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cystadenocarcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T14:01:38.001Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00085358",
      "title": "Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brenner Tumor",
        "Fallopian Tube Cancer",
        "Ovarian Carcinosarcoma",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mixed Epithelial Carcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Ovarian Undifferentiated Adenocarcinoma",
        "Primary Peritoneal Cavity Cancer",
        "Stage II Ovarian Epithelial Cancer",
        "Stage III Ovarian Epithelial Cancer",
        "Stage IV Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2004-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-07-22",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 16,
      "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085358"
    },
    {
      "nct_id": "NCT00238342",
      "title": "Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "proteomic profiling",
          "type": "GENETIC"
        },
        {
          "name": "surface-enhanced laser desorption/ionization-time of flight mass spectrometry",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2000,
      "start_date": "2005-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-02-09",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 107,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Burbank, California + 80 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00238342"
    },
    {
      "nct_id": "NCT00002913",
      "title": "Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brenner Tumor",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mixed Epithelial Carcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Ovarian Undifferentiated Adenocarcinoma",
        "Stage III Ovarian Epithelial Cancer",
        "Stage IV Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 30,
      "start_date": "1996-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002913"
    },
    {
      "nct_id": "NCT04814108",
      "title": "A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uterine Serous Carcinoma"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 92,
      "start_date": "2021-07-28",
      "completion_date": "2025-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 41,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 33 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04814108"
    },
    {
      "nct_id": "NCT02235324",
      "title": "Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mucinous Adenocarcinoma of the Colon",
        "Mucinous Adenocarcinoma of the Rectum",
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Signet Ring Adenocarcinoma of the Colon",
        "Signet Ring Adenocarcinoma of the Rectum",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-03",
      "completion_date": "2018-03",
      "has_results": false,
      "last_update_posted_date": "2015-05-06",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02235324"
    },
    {
      "nct_id": "NCT00888173",
      "title": "Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Mixed Adenocarcinoma",
        "Endometrial Mucinous Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Squamous Cell Carcinoma",
        "Endometrial Transitional Cell Carcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Recurrent Uterine Corpus Carcinoma"
      ],
      "interventions": [
        {
          "name": "Brivanib Alaninate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2009-07-06",
      "completion_date": "2016-07-16",
      "has_results": true,
      "last_update_posted_date": "2017-12-06",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 35,
      "location_summary": "Aurora, Colorado • New Britain, Connecticut • Chicago, Illinois + 19 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ames",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00888173"
    },
    {
      "nct_id": "NCT00897039",
      "title": "Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Southeastern Gynecologic Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 60,
      "start_date": "2006-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00897039"
    },
    {
      "nct_id": "NCT01275664",
      "title": "Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nausea and Vomiting",
        "Ovarian Brenner Tumor",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Stage II Ovarian Cancer",
        "Stage IIA Fallopian Tube Cancer",
        "Stage IIA Ovarian Cancer",
        "Stage IIB Fallopian Tube Cancer",
        "Stage IIB Ovarian Cancer",
        "Stage IIC Fallopian Tube Cancer",
        "Stage IIC Ovarian Cancer",
        "Stage IIIA Fallopian Tube Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Primary Peritoneal Cancer",
        "Stage IIIB Fallopian Tube Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Primary Peritoneal Cancer",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer",
        "Undifferentiated Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Adjuvant Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Granisetron Transdermal Patch",
          "type": "DRUG"
        },
        {
          "name": "Management of Therapy Complications",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2011-06",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2018-05-22",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 2,
      "location_summary": "Hinsdale, Illinois • Providence, Rhode Island",
      "locations": [
        {
          "city": "Hinsdale",
          "state": "Illinois"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01275664"
    },
    {
      "nct_id": "NCT01934179",
      "title": "Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mucinous Adenocarcinoma of the Colon",
        "Mucinous Adenocarcinoma of the Rectum",
        "Signet Ring Adenocarcinoma of the Colon",
        "Signet Ring Adenocarcinoma of the Rectum",
        "Stage IIIA Colon Cancer",
        "Stage IIIA Rectal Cancer",
        "Stage IIIB Colon Cancer",
        "Stage IIIB Rectal Cancer",
        "Stage IIIC Colon Cancer",
        "Stage IIIC Rectal Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "cytology specimen collection procedure",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2013-10",
      "completion_date": "2015-09-11",
      "has_results": false,
      "last_update_posted_date": "2018-02-07",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01934179"
    },
    {
      "nct_id": "NCT00217529",
      "title": "Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2004-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-09-21",
      "last_synced_at": "2026-06-10T14:01:38.001Z",
      "location_count": 3,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217529"
    }
  ]
}